3Langenickel T,Pagel I,Hohnel K,et al.Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart faiure.Am J Physiol Heart Circ Physiol,2000,278(5):H1500-H1506.
4Walther T,Heringer-walther S,Tschope R,et al.Opposite regulation of brain and c-type natriuretic peptides in the streptozotocin-diabetic cardiopathy.J Mol Endocrinal,2000,24(3):391-395.
5Ohuchi H,Takasugi H,Ohashi H,et al.Stratification of pediatric heart failure on the basis of neurohormonal and cardiac automic nervous activities in patients with congenital heart disease.Circulation,2003,108 (19):2368-2376.
6Maisel AS,Koon J,Krishnaswamy P,et al.Utility of B-nutriuretic as a rapid,point-of-care test for screening patients undergoing echocardio-graphy to determine left ventricular dysfunction,Am Heart J,2001,141 (3):367-374.
8Akyurek O,Akyurek N,Sayin T,et al.Association between the severity of heart failure and the susceptibility of myocytes to apoptosis in patients with idiopathic dialated cardiomyopathy.Int J Cardiol,2001,80 (1):29-36.
9Yamaoka M,Yamaguchi S,Suzuki T,et al.Apoptosis in rat cardiac myocytes induced by Fas ligand:priming for Fas-mediated apoptosis with doxorubicin.J Mol Cell Cardial,2000,32(6):881-889.
10DeWindt LJ,Lim HW,Taigen T,et al.Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and vivo:an apoptosis-independent model of dilated heart failure.Circ Res,2003,86 (3):255-263.
2Collucci WS. Molecular and cellular mechanism of myocardial failure. Am J Cardiol, 1997, 80: 15L - 25L.
3Hermann DD. Beta-adrenergic blockade 2002: a pharmacologic adyssey in chronic heart failure. Congst Heart Fail, 2002, 8(5) :262 - 269.
4Buchhorn R, Hulpke-Wette M, Ruscheuski W, et al.Effects of therapeutic beta blockade on myocardial function and cardiac remodeling in congenital cardiac disease. Cardiol Young, 2003, 13(1) :36- 43.
5PattersonJH, Rodgers JE. Expanding role of betablockade in the management of chronic heart failure.Pharmacotherapy, 2003, 23(4) :451 - 459.
6Taegtmeyer H, Dietz GJ. Perspective: from increased energy metabolism to cardiac hypertrophy and failure:mediators and molecular mechanisms. Am J Cardiol,1999, 83: 1H - 2H.
7Pritchett AM, Redfield MM. Beta-blockers: new standard therapy for heart failure. Mago Clin Pro, 2002, 77(8) :839- 845.
8Mortia H, Suzuki G, Mishima T, et al. Effects of longterm monotherapy with Metoprolol CR/XL on the progress of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Cardiovasc Drug Ther, 2002, 16(5): 443 - 449.
9Metra M, Nodari S, Parrinello G, et al. Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure:clinic correlates and prognostic significance.Am Heart J, 2003, 145(2) :292- 299.
